Form 4: Neumora Therapeutics Grants Options to Director Kristina Burow

Director and major shareholder Kristina Burow received 80,000 stock options with an exercise price of $1.86 as part of her compensation.

Summary

• Kristina Burow, a Director and 10% owner of Neumora Therapeutics, was granted 80,000 stock options on May 27, 2026.
• The options carry an exercise price of $1.86 per share.
• The grant is scheduled to vest 100% on the earlier of May 27, 2027, or the date of the next Annual Meeting.
• The options have a ten-year term, expiring on May 26, 2036.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral to slightly positive administrative event that confirms continued insider commitment and alignment with shareholders.

Positives

• Aligns the interests of a key director and major shareholder with those of common stockholders.
• The ten-year expiration date suggests a long-term commitment to the company's growth.
• Equity-based compensation preserves cash for the company's research and development activities.

Negatives

• Represents potential future dilution of 80,000 shares for existing shareholders.
• The low exercise price of $1.86 may indicate a lower valuation relative to previous periods or high volatility.

Risks

• The value of the compensation is entirely dependent on the stock price exceeding $1.86 before 2036.
• Market volatility in the biotechnology sector could render the options out-of-the-money.

Future Outlook

The grant reinforces a long-term incentive structure for board members, focusing on value creation over the next decade.

Management Comments

• 100% of the shares subject to the option vest on the earlier of the one year anniversary of May 27, 2026 or immediately prior to the next Annual Meeting.

Industry Context

StockSavvy.ai notes that equity-heavy compensation for directors is a standard practice in the clinical-stage biotechnology industry to align leadership with long-term clinical and regulatory milestones.

Comparison to Industry Standards

• The grant size of 80,000 options is consistent with director compensation packages at peer biotechnology firms like Denali Therapeutics and Sage Therapeutics.
• A one-year cliff vesting schedule for director options is a standard corporate governance practice among NASDAQ-listed life sciences companies.

Corporate Governance

Related Party Transactions

• The issuance of stock options to Kristina Burow, who is both a Director and a 10% owner, constitutes a related party transaction under SEC guidelines.

Stakeholder Impact

• Shareholders may experience minor dilution upon the eventual exercise of these options.
• The board of directors maintains stability with the continued incentivization of a major stakeholder.

Next Steps

• Vesting of the options on May 27, 2027, or the next annual meeting of stockholders.

Key Dates

Recommendation

This is a routine compensation-related filing that does not change the fundamental valuation of the company, though it confirms the ongoing involvement of a significant institutional-linked director.

Keywords

Neumora Therapeutics, NMRA, Insider Trading, Stock Options, Kristina Burow, Director Compensation, Biotechnology, SEC Form 4